Levosimendan Kalceks (Levosimendan)

Levosimendan enhances cardiac contractility by sensitizing troponin C to calcium, allowing stronger heart muscle contractions without increasing intracellular calcium. It also opens ATP‑sensitive potassium channels in vascular smooth muscle, causing vasodilation and reducing afterload, which together improve overall cardiac performance.

The dosing regimen for Levosimendan Kalceks is determined by the prescribing clinician based on the patient’s condition, severity of heart failure, and response to therapy. Healthcare professionals adjust the infusion rate and duration according to established clinical guidelines and individual patient needs.

Safety data for levosimendan in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and any required import documentation.

Levosimendan differs from traditional inotropes such as dobutamine by increasing contractility through calcium sensitization rather than raising intracellular calcium, which may reduce the risk of calcium‑mediated arrhythmias. Additionally, its vasodilatory effect can lower afterload, whereas dobutamine primarily raises heart rate and contractility without significant vasodilation.

Levosimendan Kalceks must be stored refrigerated between 2 °C and 8 °C. Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking the solution. Once removed from refrigeration, use the product within the time frame specified by the manufacturer.

Levosimendan is given as an intravenous infusion, typically initiated with a loading dose followed by a continuous maintenance infusion. Administration is performed in a monitored clinical setting, allowing healthcare professionals to observe hemodynamic responses and adjust the infusion rate as needed.

The most serious risks include severe hypotension, ventricular arrhythmias, myocardial ischemia, and rare allergic reactions such as anaphylaxis. Patients should be closely monitored for blood pressure changes, cardiac rhythm disturbances, and any signs of hypersensitivity throughout the infusion.

Levosimendan is contraindicated in patients with severe hypotension (systolic blood pressure < 90 mmHg), mechanical obstruction of the outflow tract, known hypersensitivity to the drug or its excipients, and in those receiving concurrent potent vasodilators that could cause dangerous blood pressure drops.